Anti-CMV Ig M | Anti-CMV Ig G | Anti-CMVIg G | |||
+ | + | + | + | - | |
+ | - | - | - | + | |
+ | + | + | + | - | |
- | - | - | - | + |
.
:
- (, .);
- ( );
- 14-21 , ;
- :
1) ( , , , , , );
2) , , ;
3) ;
4)
5) G
12. :
1) : , 38,5, , , , , , , , , , , , .
, .
.
- ( 4-6 ) , , .
- 3 .
- -, .
- -.
- :
) : , , , , , .
) : , , , .
2)
- : (76%), 70%, (67%), (60%), (53%), (50%), (34%), (20%), 20%, 20%. . , , , , , , .. , 3-5 . , , , .
|
|
, .
, . . - , , , . . .
- : , ǻ- , , , , , , , (, , ) , , , ( ), , , , , , , - ( , , , , , , ( ).
, , . Ÿ .
3) .
:
- , ( : 4-9109/);
-
- 4 ( ).
- , ,
- : , ( , , , , )
4) :
: , , ; .
5) :
1) .
2) - .
3) .
4) .
5) .
|
|
6) .
7) - .
12.6) :
- | - | . | |||
+ | ++ | ++ | + | + | |
+ | - | ++ | - | - | |
+ | + | + | + | + | |
+ | + | - | - | - | |
+ | - | ++ | - | + | |
+ | - | + | - | - | |
- | - | + | - | - | |
++ | + | + | + | + | |
- | - | + | - | ++ | |
++ | - | + | + | - | |
+ | - | - | + | - | |
+ | + | ++ | + | + | |
-- | -- | -- | -- | +- |
13. :
1. .
14. :
14.1. :
- ;
;
14.2. [1,2,4,10]:
: :
- 2 / ( 1/) IgG 1-4 . : 2 // 1 , 3-5 4 // 3 : 1- , 5- 9- . 2 // 1-3 ( ).
-.
- () / 5-7,5 // 2 12 ( ), 14-21 ( ).
- -2 () 150000 ( ), 500000 ( 3 ), 1000000 ( 3 ) 1 2 10-14 3 3 ( ).
- :
- : ( 4-6 - 0,15 (1 .), 7-11 - 0,3 (2 .), 12 - 0,45 (3 .) 1 per os 1,2,4,6,8,11,14,17,21,23 ., : 6-10 / / / 1 10 ( ).
- :
: , , . , , . ( , , , - ..) (, , ).
- :
:
1 150 000 , 500 000 , 1 000 000 .
2. () / 5-7,5 // 2 , 14-21 .
3. ()10% - 2 / 1 / 1 3
:
1. - 12,5%-2,0.
2. :
1. 5%, 10%.
2. 0,9% .
3.
4. (, ) 6%, 10%.
|
|
5.
14.3. :.
14.4. :
, .
14.5. :
- ;
- 1,3,6 12 ;
- ;
15. :
;
( );
- IgM - IgG ;
- IgG .
III. :
16. :
1. . - ..., , . .
2. . ..., , . .
3. - ..., ,
17. : .
18. :
1. .. - ..., .
2. , ...,
19. :
- - ;
- ;
- , .
20. :
1. , ( , ). . . 2002 .
2. / .. / . . .., .. - , 1998.
3. .. / . -1997. - 2. - . 35 38.
4. .., .., .. . torch- . - .-.-1998. - .35.
5. .., .., .., .. (, , ) - . .: , 1999. 56 .
6. .., .., .. . // - . ., 1998. - .27.
7. . ., .. : , , , / . -1998. - N 3. - . 7 13.
8. . ., . ., . . / . 1998. 4. - . 13- 18.
9. Zalel Y, Gilboa Y, Berkenshtat M, Yoeli R, Auslander R, Achiron R, et al. Secondary cytomegalovirus infection can cause severe fetal sequelae despite maternal preconceptional immunity. Ultrasound Obstet Gynecol. 2008;31:41720. The authors stated that there are no conflicts of interest regarding the publication of this article. PreviouslypublishedonlineAugust 13, 2009.
|
|
10. Britt W.J. Human cytomegalovirus infection during pregnancy. Herpes; 1996; 3(2): 37-43.
IV. ( / ):
1.
100% | |||
100% | |||
100% | |||
100% | |||
100% | |||
100% | |||
, , | 70% | ||
20% | |||
50% | |||
30% | |||
, | 30% | ||
10% | |||
- . | 50% | ||
25% | |||
- | 25% | ||
. | 70% | ||
50% | |||
60% | |||
70% | |||
( , , , , ) | 70% |
2.
() | ||||
-2 () - 150000 ( ), 500000 ( 3 ), 1000000 ( 3 ), 3000000 () | 2 | 3 | 80% | |
() - (10% , 1 100 50 ) | 6 | 80% | ||
() | / 5-7,5 // 2 | 14-21 | 40% | |
6-10 / 1 / / | 1,2,4,6,8,11,14,17,21,23 | 40% | ||
5%, 10% | 200-400 | 50% | ||
200-400 | 50% | |||
6%, 10% | 400 | 50% | ||
- | 200-400 | 50% | ||
200-400 | 50% |